Point72 Asia Singapore Pte. Ltd. Makes New $65,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,612 shares of the specialty pharmaceutical company’s stock, valued at approximately $65,000. Point72 Asia Singapore Pte. Ltd. owned 0.09% of Eagle Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC boosted its position in Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares during the period. Mackenzie Financial Corp bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $60,000. Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $71,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $76,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in shares of Eagle Pharmaceuticals in the first quarter valued at about $83,000. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Stock Down 54.8 %

EGRX opened at $0.90 on Friday. Eagle Pharmaceuticals, Inc. has a twelve month low of $0.75 and a twelve month high of $14.78. The company has a 50-day simple moving average of $4.19 and a 200 day simple moving average of $4.53. The stock has a market capitalization of $11.69 million, a price-to-earnings ratio of 0.76 and a beta of 0.51.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Eagle Pharmaceuticals in a research report on Friday. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.